WEBVTT 00:00:00.000 --> 00:00:02.419 Welcome to The Deep Dive, the show where we really 00:00:02.419 --> 00:00:05.400 try and unravel complex medical conditions, pulling 00:00:05.400 --> 00:00:08.060 out those crucial insights you need to sharpen 00:00:08.060 --> 00:00:11.019 your clinical acumen and, well, navigate some 00:00:11.019 --> 00:00:13.759 challenging patient presentations. Indeed. Today, 00:00:13.859 --> 00:00:16.559 we're embarking on a, I think, truly immersive 00:00:16.559 --> 00:00:19.820 exploration of a condition that, despite its 00:00:19.820 --> 00:00:22.260 benign classification, consistently presents 00:00:22.260 --> 00:00:24.320 clinicians like yourselves with a formidable 00:00:24.320 --> 00:00:27.920 diagnostic puzzle and, frankly, equally complex 00:00:27.920 --> 00:00:32.200 therapeutic dilemmas. We're talking about pigmented 00:00:32.200 --> 00:00:35.619 villanodular synovitis, PVNS. That's right. For 00:00:35.619 --> 00:00:38.299 you, our mid -senior medical professional listeners, 00:00:38.479 --> 00:00:40.619 getting to grips with the nuances of PVNS isn't 00:00:40.619 --> 00:00:42.479 just about expanding your knowledge base, is 00:00:42.479 --> 00:00:45.259 it? It's really about making a tangible difference 00:00:45.259 --> 00:00:47.640 in patient outcomes, often in cases that have 00:00:47.640 --> 00:00:50.140 perhaps baffled others for a long time. Absolutely. 00:00:50.429 --> 00:00:52.649 So to kick us off, perhaps you could explain 00:00:52.649 --> 00:00:55.750 what is the fundamental nature of PVNS and what 00:00:55.750 --> 00:00:58.070 is it that makes it such a perplexing condition 00:00:58.070 --> 00:01:00.329 for those of us in clinical practice? Well, thank 00:01:00.329 --> 00:01:03.770 you. Pigmented Villinodular Cenovitis, PVNS, 00:01:04.450 --> 00:01:07.730 is fundamentally a rare condition. It's benign, 00:01:07.870 --> 00:01:11.230 yes, but locally very aggressive. It's a proliferative 00:01:11.230 --> 00:01:13.409 disorder specifically affecting the synovium. 00:01:13.569 --> 00:01:16.010 The joint lining. Exactly. the joint lining. 00:01:16.390 --> 00:01:18.230 And it's crucial to understand that whilst it's 00:01:18.230 --> 00:01:20.590 considered a subtype of 10 of synovial giant 00:01:20.590 --> 00:01:23.769 cell tumors, it's not actually a true neoplasm 00:01:23.769 --> 00:01:26.150 in the malignant sense. Right. But, and this 00:01:26.150 --> 00:01:28.969 is the key thing, its behavior can be remarkably 00:01:28.969 --> 00:01:31.969 aggressive locally. It can lead to significant 00:01:31.969 --> 00:01:35.230 and often irreversible joint damage if it's not 00:01:35.230 --> 00:01:37.250 identified and managed appropriately. So how 00:01:37.250 --> 00:01:39.469 does that compare to normal synovium? Well, think 00:01:39.469 --> 00:01:42.129 of the synovium in a healthy joint. It's a remarkably 00:01:42.129 --> 00:01:45.780 thin, quite delicate membrane. Its job is producing 00:01:45.780 --> 00:01:48.659 synovial fluid, that vital lubricant which allows 00:01:48.659 --> 00:01:51.060 our cartilage to glide smoothly, lets our joints 00:01:51.060 --> 00:01:54.859 move without friction. In PDNS, this normally 00:01:54.859 --> 00:01:57.599 delicate lining undergoes dramatic uncontrolled 00:01:57.599 --> 00:02:00.599 proliferation. It thickens up immensely, overgrows 00:02:00.599 --> 00:02:03.459 into a dense mass really, and produces an excessive 00:02:03.459 --> 00:02:05.859 amount of fluid. So you get swelling. Exactly. 00:02:06.299 --> 00:02:09.030 Significant swelling. And this accumulation, 00:02:09.449 --> 00:02:11.389 coupled with the sheer bulk of the proliferating 00:02:11.389 --> 00:02:14.310 tissue, resulting in considerable swelling, chronic 00:02:14.310 --> 00:02:17.229 pain, and ultimately a sort of relentless assault 00:02:17.229 --> 00:02:19.830 on the joint architecture itself. And the long 00:02:19.830 --> 00:02:22.110 -term consequences. The real long -term impact 00:02:22.110 --> 00:02:24.930 for patients is its potential for progressive 00:02:24.930 --> 00:02:27.930 joint destruction. We're talking about direct 00:02:27.930 --> 00:02:31.189 erosion of the articular cartilage, cystic remodeling, 00:02:31.530 --> 00:02:33.629 destruction of the underlying subchondral bone. 00:02:33.729 --> 00:02:36.930 Wow. ultimately profound functional impairment 00:02:36.930 --> 00:02:40.250 and significant morbidity if the condition remains 00:02:40.250 --> 00:02:42.569 untreated. And where do we typically see this? 00:02:42.969 --> 00:02:46.169 Well, PVNS can manifest in virtually any joint, 00:02:46.569 --> 00:02:48.849 technically, but the knee is by far the most 00:02:48.849 --> 00:02:52.449 commonly affected. It accounts for up to 80 % 00:02:52.449 --> 00:02:54.909 of all reported cases. 80 %? That's high. It 00:02:54.909 --> 00:02:57.270 is. But we also frequently encounter it in the 00:02:57.270 --> 00:02:59.729 hip. the ankle, the shoulder, and even the elbow. 00:03:00.150 --> 00:03:01.909 And depending on the joint involved, that often 00:03:01.909 --> 00:03:03.990 poses quite significant diagnostic challenges. 00:03:04.150 --> 00:03:06.129 That immediately highlights the core paradox, 00:03:06.289 --> 00:03:09.349 doesn't it? Yeah. Benign by definition, yet potentially 00:03:09.349 --> 00:03:11.990 devastating in its local impact. It's certainly 00:03:11.990 --> 00:03:13.530 a condition that sounds like it could slip under 00:03:13.530 --> 00:03:16.830 the radar quite easily. It does. OK, let's unpack 00:03:16.830 --> 00:03:20.009 this a bit more. Given its complex nature and 00:03:20.009 --> 00:03:22.229 that destructive potential you've outlined, who 00:03:22.229 --> 00:03:25.349 is most typically affected by PVNS? And just 00:03:25.349 --> 00:03:28.099 how prevalent is it really? That rarity must 00:03:28.099 --> 00:03:30.479 contribute to the diagnostic delay you mentioned. 00:03:31.180 --> 00:03:33.680 You've hit on a critical point there. Its rarity 00:03:33.680 --> 00:03:36.259 is indeed a major factor in the diagnostic puzzle. 00:03:36.419 --> 00:03:39.319 To put it into perspective, population -based 00:03:39.319 --> 00:03:42.039 incidence data, mainly from the U .S., actually, 00:03:42.300 --> 00:03:44.460 suggests it's truly uncommon. We're looking at 00:03:44.460 --> 00:03:47.539 approximately 9 .2 new cases per million people 00:03:47.539 --> 00:03:50.210 diagnosed annually. Per million per year. So 00:03:50.210 --> 00:03:52.909 really not common. Not common at all. This low 00:03:52.909 --> 00:03:54.889 incidence means that for many clinicians, it's 00:03:54.889 --> 00:03:56.830 simply not a condition they encounter frequently. 00:03:57.430 --> 00:04:00.310 So naturally, it often gets overlooked in those 00:04:00.310 --> 00:04:02.289 initial differential diagnoses. Makes sense. 00:04:02.509 --> 00:04:04.789 And the typical patient. In terms of the patient 00:04:04.789 --> 00:04:08.710 profile, PVNS primarily affects young to middle 00:04:08.710 --> 00:04:12.449 -aged adults, typically those between, say, 20 00:04:12.449 --> 00:04:15.449 and 50 years of age. There's a noticeable peak 00:04:15.449 --> 00:04:17.569 incidence observed in patients in their third 00:04:17.569 --> 00:04:20.750 and fourth decades, so specifically between 30 00:04:20.750 --> 00:04:24.069 and 40 years old. Now, whilst they can theoretically 00:04:24.069 --> 00:04:27.290 occur at any age, it is exceedingly rare in pediatric 00:04:27.290 --> 00:04:29.949 populations. And that must cause issues. It does, 00:04:30.029 --> 00:04:32.269 unfortunately. When it does present in children, 00:04:32.389 --> 00:04:34.529 it's often misdiagnosed for extended periods. 00:04:34.829 --> 00:04:37.470 Its presentation can be particularly atypical 00:04:37.470 --> 00:04:40.310 in younger patients, leading to delays in appropriate 00:04:40.310 --> 00:04:43.149 management and potentially more advanced disease 00:04:43.149 --> 00:04:45.750 by the time of diagnosis. Right. What about gender? 00:04:45.910 --> 00:04:47.350 Is there a difference between men and women? 00:04:47.569 --> 00:04:49.629 That's interesting, actually. The data offers 00:04:49.629 --> 00:04:51.889 a slightly mixed picture, which can add to the 00:04:51.889 --> 00:04:55.529 diagnostic ambiguity sometimes. Some large -scale 00:04:55.529 --> 00:04:58.410 epidemiological studies indicate and approximately 00:04:58.410 --> 00:05:00.970 equal incidence in men and women, suggesting 00:05:00.970 --> 00:05:03.470 no significant gender predisposition overall. 00:05:03.990 --> 00:05:07.110 However, other investigations, particularly those 00:05:07.110 --> 00:05:10.370 focusing on specific cohorts or perhaps the different 00:05:10.370 --> 00:05:13.350 forms of the disease, suggest a slight female 00:05:13.350 --> 00:05:17.089 predominance, especially it seems in the localized 00:05:17.089 --> 00:05:20.290 form of PVNS. So maybe a slight leaning towards 00:05:20.290 --> 00:05:23.829 women, particularly for the localized type? Possibly. 00:05:24.089 --> 00:05:26.449 It's a nuance clinicians might keep in mind, 00:05:26.810 --> 00:05:29.129 though it's certainly not a definitive diagnostic 00:05:29.129 --> 00:05:31.410 criterion. Understood. You mentioned diagnostic 00:05:31.410 --> 00:05:34.029 delay earlier. Yes, and perhaps one of the most 00:05:34.029 --> 00:05:36.550 clinically significant epidemiological features 00:05:36.550 --> 00:05:40.939 is its insidious onset. Patients frequently experience 00:05:40.939 --> 00:05:43.240 symptoms for a considerable period, sometimes 00:05:43.240 --> 00:05:46.100 years, before a definitive diagnosis is finally 00:05:46.100 --> 00:05:49.220 made. Years? It can be. The median time from 00:05:49.220 --> 00:05:51.399 the initial onset of symptoms to a confirmed 00:05:51.399 --> 00:05:54.439 diagnosis is often reported to be around 18 months. 00:05:54.899 --> 00:05:57.360 Though it can certainly be longer in some cases. 00:05:57.629 --> 00:06:00.709 This prolonged diagnostic delay is a major contributor 00:06:00.709 --> 00:06:02.949 to the progressive joint damage we often see 00:06:02.949 --> 00:06:05.250 because the condition just continues its destructive 00:06:05.250 --> 00:06:07.810 process unchecked. That really underscores why 00:06:07.810 --> 00:06:09.769 increased awareness is so important, doesn't 00:06:09.769 --> 00:06:12.230 it, for GPs and specialists alike? Absolutely. 00:06:12.689 --> 00:06:14.850 Earlier identification and intervention are key. 00:06:15.089 --> 00:06:17.490 18 months is a significant amount of time for 00:06:17.490 --> 00:06:20.329 a patient to endure unexplained pain and functional 00:06:20.329 --> 00:06:24.089 decline. That insidious onset coupled with its 00:06:24.089 --> 00:06:26.649 rarity. Well, it certainly explains why it's 00:06:26.649 --> 00:06:28.990 such a diagnostic conundrum. It is. Now, here's 00:06:28.990 --> 00:06:30.930 where it gets really interesting for us clinicians. 00:06:32.050 --> 00:06:34.269 What do we currently understand about the underlying 00:06:34.269 --> 00:06:37.449 causes and the pathological processes that actually 00:06:37.449 --> 00:06:39.990 drive this condition? It sounds like there must 00:06:39.990 --> 00:06:43.319 be a specific biological engine. behind this 00:06:43.319 --> 00:06:46.120 unusual overgrowth, something beyond just simple 00:06:46.120 --> 00:06:49.220 proliferation. Indeed. Understanding the underlying 00:06:49.220 --> 00:06:52.759 pathophysiology is absolutely key to appreciating 00:06:52.759 --> 00:06:55.759 both its behavior and actually the rationale 00:06:55.759 --> 00:06:57.660 behind some of the emerging targeted therapies. 00:06:58.000 --> 00:07:00.160 Right. While the precise initiating cause of 00:07:00.160 --> 00:07:03.459 PDNS still largely remains unknown, our understanding 00:07:03.459 --> 00:07:06.120 of its genetic and molecular underpinnings has 00:07:06.120 --> 00:07:08.259 advanced dramatically in recent decades. OK, 00:07:08.279 --> 00:07:10.360 what have we found? The most pivotal discovery, 00:07:10.439 --> 00:07:12.399 the one that's truly transformed our sites into 00:07:12.399 --> 00:07:15.279 PVNS is the identification of specific genetic 00:07:15.279 --> 00:07:18.399 translocations. Translocations. Yes. In the overwhelming 00:07:18.399 --> 00:07:21.759 majority of PVNS cases, we find translocations 00:07:21.759 --> 00:07:24.939 involving chromosome 1P13. Right, 1P13. This 00:07:24.939 --> 00:07:26.800 particular genetic rearrangement leads directly 00:07:26.800 --> 00:07:29.639 to the overexpression of the gene encoding colony 00:07:29.639 --> 00:07:32.459 stimulating factor 1, or CSF1, and importantly, 00:07:32.879 --> 00:07:36.879 its corresponding receptor CSF1R. CSF1 and its 00:07:36.879 --> 00:07:41.319 receptor CSF1R. OK. This CSF1 -CSF1R pathway 00:07:41.319 --> 00:07:44.759 is crucial. When CSF1 is overexpressed, it acts 00:07:44.759 --> 00:07:47.550 as a potent growth factor. It attracts and promotes 00:07:47.550 --> 00:07:50.129 the proliferation of various inflammatory cells, 00:07:50.569 --> 00:07:52.470 particularly macrophages, and their precursors, 00:07:52.689 --> 00:07:55.110 which express the CSF1R on their surface. So 00:07:55.110 --> 00:07:57.490 it draws in these cells? Precisely. And what 00:07:57.490 --> 00:07:59.449 happens then is a fascinating but ultimately 00:07:59.449 --> 00:08:02.189 destructive cascade. This over -expression triggers 00:08:02.189 --> 00:08:04.810 the formation of aberrant cell clusters, essentially 00:08:04.810 --> 00:08:07.350 creating focal areas of soft tissue hyperplasia, 00:08:07.670 --> 00:08:09.589 specifically within the synovial lining cells. 00:08:09.839 --> 00:08:12.759 These cells, driven by the CSF1 signaling, then 00:08:12.759 --> 00:08:14.639 begin to form that characteristic thickened, 00:08:14.720 --> 00:08:16.839 overgrown synovial tissue we observe in PVNS. 00:08:16.920 --> 00:08:18.699 That's the engine, then? That's the main engine, 00:08:18.759 --> 00:08:23.040 yes. Beyond the 1P13 translocation, other associated 00:08:23.040 --> 00:08:25.620 chromosomal abnormalities have also been identified, 00:08:25.920 --> 00:08:28.459 though less commonly. Things like a 5 -key -33 00:08:28.459 --> 00:08:30.959 rearrangement, and even prismes of chromosomes 00:08:30.959 --> 00:08:34.440 7 and 5. These further suggest a complex genetic 00:08:34.440 --> 00:08:37.059 predisposition influencing the disease's development. 00:08:37.279 --> 00:08:39.740 So it's complex genetically. It is. But it's 00:08:39.740 --> 00:08:44.000 this fundamental dysregulation of the CSF1R signaling 00:08:44.000 --> 00:08:47.500 pathway that directly underlies the locally aggressive, 00:08:47.620 --> 00:08:50.570 albeit technically benign nature of the disease, 00:08:50.970 --> 00:08:53.110 it's what drives the uncontrolled synovial thickening 00:08:53.110 --> 00:08:54.549 and overgrowth. And what does that look like 00:08:54.549 --> 00:08:56.950 under the microscope when you get a biopsy? Ah, 00:08:56.990 --> 00:09:00.090 yes. When we examine biopsy samples, the histological 00:09:00.090 --> 00:09:02.590 hallmarks are indeed quite distinctive. They 00:09:02.590 --> 00:09:04.649 tell a compelling story of the disease's activity. 00:09:04.870 --> 00:09:07.429 Such as? Microscopically, we observe a proliferation 00:09:07.429 --> 00:09:11.590 of rare, polyhedral synovial -like cells. These 00:09:11.590 --> 00:09:13.789 are the main cellular component of the overgrown 00:09:13.789 --> 00:09:16.480 synovium. Crucially, there are abundant multi 00:09:16.480 --> 00:09:19.200 -nucleated giant cells, which are essentially 00:09:19.200 --> 00:09:22.539 fused macrophages. Now, these giant cells aren't 00:09:22.539 --> 00:09:25.279 specific only to PVNS, but seeing lots of them 00:09:25.279 --> 00:09:28.039 is a strong indicator of an active inflammatory 00:09:28.039 --> 00:09:31.519 or proliferative process. Perhaps the most pathognomonic 00:09:31.519 --> 00:09:33.889 feature, though, is the extensive hemocytarin 00:09:33.889 --> 00:09:37.090 deposition. Hemocytarin, iron deposits. Exactly. 00:09:37.470 --> 00:09:40.269 Hemocytarin is an iron storage complex. And these 00:09:40.269 --> 00:09:42.710 hemocytarin -laden macrophages, often described 00:09:42.710 --> 00:09:45.450 as pigmented foam cells, are what impart the 00:09:45.450 --> 00:09:48.129 characteristic brown, reddish, or sometimes even 00:09:48.129 --> 00:09:50.870 blackish coloration to the affected tissue. Ah, 00:09:50.929 --> 00:09:53.629 the pigmented part of the name. Precisely. This 00:09:53.629 --> 00:09:56.210 pigmentation is a direct visual indicator of 00:09:56.210 --> 00:09:59.149 recurrent, often subclinical, bleeding into the 00:09:59.149 --> 00:10:02.500 joint space. That's a hallmark of PVNS due to 00:10:02.500 --> 00:10:04.820 the fragility and high vascularity of the abnormal 00:10:04.820 --> 00:10:06.519 synovium. Makes sense. What else do you see? 00:10:06.820 --> 00:10:09.139 We also consistently see mononuclear stromal 00:10:09.139 --> 00:10:12.559 cells. These are actually thought to be the neoplastic 00:10:12.559 --> 00:10:16.500 cell population responsible for the CSF1 overexpression. 00:10:17.600 --> 00:10:21.080 The tissue typically forms highly vascular villi, 00:10:21.220 --> 00:10:23.940 sort of frond -like projections lined with plump, 00:10:23.980 --> 00:10:26.950 hyperplastic synovial cells. And frequently, 00:10:27.470 --> 00:10:29.809 common mitotic figures are observed, which confirms 00:10:29.809 --> 00:10:34.580 active cellular proliferation is occurring. Like 00:10:34.580 --> 00:10:36.740 arthritis? Well, there's an intriguing hypothesis 00:10:36.740 --> 00:10:39.159 regarding an inflammatory component, yes. It 00:10:39.159 --> 00:10:41.200 draws some parallels with other chronic arthritic 00:10:41.200 --> 00:10:43.120 conditions, although it's certainly distinct 00:10:43.120 --> 00:10:46.080 from classical inflammatory arthropathies. Some 00:10:46.080 --> 00:10:47.879 studies have explored a potential link between 00:10:47.879 --> 00:10:51.320 prior joint injuries and the onset of PVNS. Trauma? 00:10:51.559 --> 00:10:53.700 Yes, suggesting that trauma might act as a trigger 00:10:53.700 --> 00:10:56.700 or perhaps a predisposing factor in genetically 00:10:56.700 --> 00:10:59.190 susceptible individuals. However, it's important 00:10:59.190 --> 00:11:01.009 for us to note that this correlation hasn't been 00:11:01.009 --> 00:11:03.950 consistently or definitively proven across all 00:11:03.950 --> 00:11:06.350 investigations. Many patients have absolutely 00:11:06.350 --> 00:11:08.870 no history of significant trauma. So maybe a 00:11:08.870 --> 00:11:12.669 link, but not definite. Exactly. Whilst an association 00:11:12.669 --> 00:11:15.789 is often reported in patient histories, a direct 00:11:15.789 --> 00:11:19.399 causative link remains largely unconfirmed. That's 00:11:19.399 --> 00:11:21.700 a profound explanation though, connecting the 00:11:21.700 --> 00:11:24.799 macroscopic presentation directly to that underlying 00:11:24.799 --> 00:11:27.620 genetic and cellular dysregulation. It's really 00:11:27.620 --> 00:11:29.840 clear that understanding this molecular engine 00:11:29.840 --> 00:11:33.460 of PVNS is vital, especially for developing targeted 00:11:33.460 --> 00:11:35.899 therapies. Absolutely. Now, you mentioned the 00:11:35.899 --> 00:11:37.860 local aggression, but it's not all uniform, is 00:11:37.860 --> 00:11:40.419 it? Can you delineate the critical differences 00:11:40.419 --> 00:11:44.120 between localized and diffuse PVNS? As I understand 00:11:44.120 --> 00:11:46.580 it, this distinction isn't just academic. It 00:11:46.580 --> 00:11:49.120 has pretty profound implications for both prognosis 00:11:49.120 --> 00:11:51.799 and the treatment strategies we choose. You're 00:11:51.799 --> 00:11:53.899 absolutely right. The distinction between localized 00:11:53.899 --> 00:11:57.419 and diffuse forms of PDNS is not merely a classification. 00:11:57.940 --> 00:12:00.179 It's a fundamental determinant of clinical behavior, 00:12:00.379 --> 00:12:03.179 prognosis, and most importantly, our therapeutic 00:12:03.179 --> 00:12:05.820 approach. This classification guides virtually 00:12:05.820 --> 00:12:07.860 every decision we make in patient management. 00:12:08.019 --> 00:12:10.799 Okay, so let's start with localized. Right. Localized 00:12:10.799 --> 00:12:13.240 PVNS. This is also frequently referred to as 00:12:13.240 --> 00:12:16.200 the nodular or sometimes the classic form. As 00:12:16.200 --> 00:12:18.340 the name suggests, this variant is characterized 00:12:18.340 --> 00:12:20.899 by a more confined proliferation. Contained. 00:12:21.100 --> 00:12:23.879 Exactly. The tumor typically involves specific 00:12:23.879 --> 00:12:26.799 tendons supporting the joint or it manifests 00:12:26.799 --> 00:12:30.379 as a well -circumscribed, often solitary nodule 00:12:30.379 --> 00:12:32.700 within just one area of the joint capsule or 00:12:32.700 --> 00:12:35.629 synovial lining. How might you feel? On physical 00:12:35.629 --> 00:12:38.529 examination, it can sometimes present as a palpable, 00:12:38.690 --> 00:12:41.730 firm nodule. It might appear skin -colored or 00:12:41.730 --> 00:12:44.629 perhaps slightly brownish. The most common site 00:12:44.629 --> 00:12:47.129 for localized PVNS, particularly within the knee, 00:12:47.470 --> 00:12:50.669 is the anterior compartment, specifically affecting 00:12:50.669 --> 00:12:53.450 the infrapatellar fat pad. The fat pad below 00:12:53.450 --> 00:12:56.129 the kneecap? Precisely. Up to 80 % of localized 00:12:56.129 --> 00:12:58.279 knee cases originate there. which makes sense 00:12:58.279 --> 00:13:00.159 clinically, as the fat pad is a common site for 00:13:00.159 --> 00:13:02.039 synovial proliferation anyway. And symptoms? 00:13:02.340 --> 00:13:04.340 From a patient's perspective, localized PDNS 00:13:04.340 --> 00:13:07.139 is often slow growing and, quite surprisingly, 00:13:07.779 --> 00:13:09.720 may be relatively painless in its early stages. 00:13:09.899 --> 00:13:13.379 Really? Painless? Relatively, yes. However, as 00:13:13.379 --> 00:13:16.240 it grows, it can certainly cause mechanical symptoms 00:13:16.240 --> 00:13:18.639 due to impingement within the joint. things like 00:13:18.639 --> 00:13:21.179 locking, catching, or maybe giving away sensations, 00:13:21.720 --> 00:13:24.340 particularly during specific movements. The key 00:13:24.340 --> 00:13:26.779 clinical takeaway here is its well -defined nature. 00:13:27.059 --> 00:13:30.460 And prognosis. Prognostically, localized PVNS 00:13:30.460 --> 00:13:33.080 generally responds very well to surgical intervention. 00:13:33.899 --> 00:13:36.039 After a complete excision, which is typically 00:13:36.039 --> 00:13:39.000 done via arthroscopic synovectomy. The recurrence 00:13:39.000 --> 00:13:42.139 rate is commendably low, usually around 8%. 8%, 00:13:42.139 --> 00:13:44.820 that's pretty good. It is, which makes it a much 00:13:44.820 --> 00:13:47.019 more manageable form of the disease. Okay, so 00:13:47.019 --> 00:13:49.779 that's localized. What about diffuse? No, in 00:13:49.779 --> 00:13:53.299 stark contrast, we have diffuse PVNS. This form 00:13:53.299 --> 00:13:56.379 is significantly more widespread and, frankly, 00:13:56.580 --> 00:13:59.019 more aggressive. How so? It involves an entire 00:13:59.019 --> 00:14:02.200 joint with extensive, often global thickening 00:14:02.200 --> 00:14:04.980 of the joint lining. A critical characteristic 00:14:04.980 --> 00:14:07.860 is its frequent tendency for extraarticular extension. 00:14:08.019 --> 00:14:10.779 Spreading outside the joint. Exactly. This means 00:14:10.779 --> 00:14:12.879 the disease isn't confined to the joint capsule. 00:14:13.299 --> 00:14:16.039 It can extend significantly beyond infiltrating 00:14:16.039 --> 00:14:19.480 surrounding soft tissues, musculature, even neurovascular 00:14:19.480 --> 00:14:21.820 structures. For example, in the knee, you might 00:14:21.820 --> 00:14:24.620 see extensive posterior extension outside the 00:14:24.620 --> 00:14:26.919 joint capsule, which makes surgical removal far 00:14:26.919 --> 00:14:30.000 more challenging. Right. On imaging, diffuse 00:14:30.000 --> 00:14:33.379 PVNS is typically ill -defined or poorly circumscribed, 00:14:33.779 --> 00:14:36.210 reflecting its infiltrative nature. And clinically? 00:14:36.409 --> 00:14:38.570 Clinically, its behavior is considerably more 00:14:38.570 --> 00:14:41.230 aggressive than the localized form. Patients 00:14:41.230 --> 00:14:43.990 with diffuse PVNS invariably experience more 00:14:43.990 --> 00:14:47.769 severe, persistent pain and profound joint dysfunction. 00:14:48.090 --> 00:14:50.610 It leads to a much greater impact on their quality 00:14:50.610 --> 00:14:53.789 of life. This widespread and infiltrative nature 00:14:53.789 --> 00:14:56.210 makes it inherently more difficult to treat effectively. 00:14:56.389 --> 00:14:59.070 Any specific signs? A frequent presentation and 00:14:59.070 --> 00:15:01.789 indeed a diagnostic hallmark of diffused PVNS 00:15:01.789 --> 00:15:04.769 is its association with long -standing hemorrhagic 00:15:04.769 --> 00:15:07.389 joint diffusions. Bleeding into the joint? Yes. 00:15:07.769 --> 00:15:11.049 Recurrent, often spontaneous. Bleeding into the 00:15:11.049 --> 00:15:13.529 joint space without a preceding traumatic event. 00:15:14.230 --> 00:15:16.429 Patients commonly present with painful masses. 00:15:16.679 --> 00:15:19.220 a markedly decreased range of motion due to the 00:15:19.220 --> 00:15:21.960 synovial thickening and the effusion and diffuse 00:15:21.960 --> 00:15:25.100 tenderness along the joint line. Recurrent atraumatic 00:15:25.100 --> 00:15:27.679 hemorrhothrosis is therefore a strong red flag 00:15:27.679 --> 00:15:30.860 for diffuse PVNS. And the prognosis here? Much 00:15:30.860 --> 00:15:32.740 worse, I imagine. Considerably less favorable, 00:15:32.960 --> 00:15:35.299 yes. Given its more aggressive nature and diffuse 00:15:35.299 --> 00:15:38.340 involvement, despite a therosurgical synovectomy, 00:15:38.740 --> 00:15:40.500 the recurrence rate is significantly higher, 00:15:40.840 --> 00:15:43.940 ranging from approximately 30 % up to 50%. 30 00:15:43.940 --> 00:15:47.080 to 50 % recurrence. That's high. It poses a substantial 00:15:47.080 --> 00:15:49.120 challenge for long -term management and often 00:15:49.120 --> 00:15:51.440 necessitates multimodal or repeated interventions. 00:15:52.200 --> 00:15:54.159 This clear distinction is absolutely tear them 00:15:54.159 --> 00:15:56.220 out for guiding our diagnostic investigations 00:15:56.220 --> 00:15:58.620 and, of course, our subsequent treatment algorithms. 00:15:58.889 --> 00:16:01.629 That's a remarkably clear delineation, and it 00:16:01.629 --> 00:16:03.809 certainly drives home why accurate classification 00:16:03.809 --> 00:16:07.309 is so pivotal. With such varying presentations, 00:16:07.450 --> 00:16:09.730 though, and that insidious onset you've mentioned, 00:16:10.269 --> 00:16:12.730 how does a clinician typically encounter a patient 00:16:12.730 --> 00:16:15.710 with PVNS? What does that first presentation 00:16:15.710 --> 00:16:18.289 often look like? Well, they usually present with 00:16:18.289 --> 00:16:21.429 joint pain. Just pain? Often, yes. Insidious 00:16:21.429 --> 00:16:24.500 onset of joint pain. It can be quite variable 00:16:24.500 --> 00:16:27.799 from a mild sort of nagging discomfort to quite 00:16:27.799 --> 00:16:31.340 severe, poorly localized pain. This is often 00:16:31.340 --> 00:16:33.980 accompanied by a sense of stiffness, particularly 00:16:33.980 --> 00:16:36.440 after periods of rest and noticeable swelling 00:16:36.440 --> 00:16:38.700 in the affected joint. And the bleeding. As we 00:16:38.700 --> 00:16:40.899 discussed, a crucial red flag, especially for 00:16:40.899 --> 00:16:43.559 the diffuse form, is that recurrent atraumatic 00:16:43.559 --> 00:16:46.379 hemarthrosis. Spontaneous bleeding into the joint 00:16:46.379 --> 00:16:49.139 without any clear injury. Patients often describe 00:16:49.139 --> 00:16:51.480 the joint as filling up with blood. What about 00:16:51.480 --> 00:16:54.019 function? Functionally, patients may experience 00:16:54.019 --> 00:16:56.139 a progressive decrease in their range of motion. 00:16:56.759 --> 00:16:59.399 They might notice a palpable mass or a sort of 00:16:59.399 --> 00:17:01.500 fullness around the joint. And they frequently 00:17:01.500 --> 00:17:04.480 complain of mechanical symptoms, locking, catching, 00:17:04.900 --> 00:17:07.160 a sensation of the joint giving way under weight 00:17:07.160 --> 00:17:09.700 bearing. Leading to limping. In more advanced 00:17:09.700 --> 00:17:13.059 cases, yes. It can manifest as a noticeable limp 00:17:13.059 --> 00:17:16.420 or just general difficulty with activities requiring 00:17:16.420 --> 00:17:18.660 use of the affected limb. And the trauma link. 00:17:18.859 --> 00:17:21.579 It's interesting, as I mentioned, about 50 % 00:17:21.579 --> 00:17:24.259 of patients might report a history of prior trauma 00:17:24.259 --> 00:17:27.619 to the affected joint. But the precise correlation 00:17:27.619 --> 00:17:30.579 remains inconsistent, so it shouldn't be relied 00:17:30.579 --> 00:17:33.339 upon as a primary diagnostic indicator. Right. 00:17:33.460 --> 00:17:35.079 It sounds like it could mimic a lot of things. 00:17:35.440 --> 00:17:37.900 Absolutely. The sheer diagnostic challenge here 00:17:37.900 --> 00:17:41.029 cannot be overstated. Because of its slow, progressive 00:17:41.029 --> 00:17:44.289 nature and these non -specific symptoms, patients 00:17:44.289 --> 00:17:47.309 frequently undergo extensive workups for a whole 00:17:47.309 --> 00:17:49.730 myriad of other conditions first. Like what? 00:17:50.009 --> 00:17:52.430 Oh, inflammatory arthrotides like rheumatoid 00:17:52.430 --> 00:17:55.349 arthritis, mechanical issues like displaced meniscal 00:17:55.349 --> 00:17:57.890 tears, infections like septic arthritis, even 00:17:57.890 --> 00:18:01.089 other benign masses such as ganglion cysts, schwannomas, 00:18:01.670 --> 00:18:04.750 or hemangiomas. PVNS is often way down the list 00:18:04.750 --> 00:18:06.869 initially. Until other things are ruled out? 00:18:07.029 --> 00:18:09.309 Often, yes. And what would you find on examination? 00:18:09.769 --> 00:18:12.190 During the physical examination, general inspection 00:18:12.190 --> 00:18:15.089 might reveal joint effusion, indicating fluid 00:18:15.089 --> 00:18:18.589 accumulation, sometimes erythema, maybe if there's 00:18:18.589 --> 00:18:20.730 an inflammatory component or acute bleeding. 00:18:21.390 --> 00:18:23.670 Palpation of the joint often elicits tenderness 00:18:23.670 --> 00:18:26.069 along the joint line, and you might feel a palpable 00:18:26.069 --> 00:18:30.230 mass or just a diffuse, boggy swelling. Limited 00:18:30.230 --> 00:18:32.789 range of motion, both active and passive, is 00:18:32.789 --> 00:18:35.900 a common and often quite profound finding. OK, 00:18:35.900 --> 00:18:39.180 so history and examination give clues. What's 00:18:39.180 --> 00:18:41.559 the comprehensive diagnostic pathway we should 00:18:41.559 --> 00:18:44.119 be pursuing, then, to actually nail the diagnosis, 00:18:44.680 --> 00:18:46.519 especially given that mimicry problem? Right. 00:18:46.519 --> 00:18:49.160 For the diagnostic tools, we employ a multimodality 00:18:49.160 --> 00:18:51.579 approach. Imaging plays a pivotal role here. 00:18:51.720 --> 00:18:54.339 Starting with x -rays. Usually, yes. X -rays 00:18:54.339 --> 00:18:56.519 are typically the initial radiographic studies. 00:18:56.740 --> 00:18:59.140 Now, they might appear normal in early PVNS or 00:18:59.140 --> 00:19:01.420 in the localized forms, but they are essential 00:19:01.420 --> 00:19:04.099 for ruling out other pathologies and can provide 00:19:04.099 --> 00:19:07.630 clues in more What sort of clues? Characteristic 00:19:07.630 --> 00:19:10.170 findings, when they're present, include soft 00:19:10.170 --> 00:19:13.269 tissue swelling and specific bone changes, cystic 00:19:13.269 --> 00:19:16.029 erosions, often with sclerotic margins, on both 00:19:16.029 --> 00:19:18.089 sides of the joint, sometimes called notching 00:19:18.089 --> 00:19:21.970 or pressure erosion, or you might see frank bone 00:19:21.970 --> 00:19:24.710 destruction, sort of punched out lesions caused 00:19:24.710 --> 00:19:26.849 by the direct pressure and erosive activity of 00:19:26.849 --> 00:19:29.250 the proliferating tumor. But x -rays aren't definitive. 00:19:29.529 --> 00:19:32.470 No, definitely not. Magnetic Resonance Imaging, 00:19:32.650 --> 00:19:35.349 MRI, is unequivocally the most sensitive and 00:19:35.349 --> 00:19:38.190 indeed the gold standard imaging study for diagnosing 00:19:38.190 --> 00:19:42.029 PVNS. Why MRI? It provides unparalleled delineation 00:19:42.029 --> 00:19:44.210 of both the intraarticular, so within the joint, 00:19:44.609 --> 00:19:47.150 and any extraarticular disease extension. It 00:19:47.150 --> 00:19:49.170 shows you exactly where it is and how far it's 00:19:49.170 --> 00:19:51.609 spread. What are the key findings on MRI? Key 00:19:51.609 --> 00:19:53.670 findings include significant joint effusion, 00:19:53.890 --> 00:19:56.349 obviously, and that characteristic synovial expansion. 00:19:56.569 --> 00:19:59.529 But the critical MRI signature, the real giveaway, 00:20:00.109 --> 00:20:02.450 relates to the hemocytorin deposits. The iron, 00:20:02.589 --> 00:20:05.089 again. Exactly. These iron deposits appear as 00:20:05.089 --> 00:20:07.650 low signal intensity on both T1 and T2 weighted 00:20:07.650 --> 00:20:10.609 images. And crucially, they produce a distinctive 00:20:10.609 --> 00:20:13.210 blooming artifact on gradient echo sequences. 00:20:13.569 --> 00:20:16.390 Blooming artifact? Yes, it's caused by the paramagnetic 00:20:16.390 --> 00:20:19.210 effect of the iron. It makes the dark areas appear 00:20:19.210 --> 00:20:21.789 much larger than they actually are on those specific 00:20:21.789 --> 00:20:25.210 sequences. This blooming artifact is highly suggestive, 00:20:25.230 --> 00:20:28.910 if not pythognomonic, of PVNS. It's a visual 00:20:28.910 --> 00:20:31.230 confirmation of that recurrent bleeding within 00:20:31.230 --> 00:20:33.920 the synovium. Very characteristic, then, any 00:20:33.920 --> 00:20:37.680 role for CT. Computed tomography, CT scans, are 00:20:37.680 --> 00:20:40.200 less sensitive for the soft tissue detail compared 00:20:40.200 --> 00:20:42.859 to MRI, but they are particularly useful for 00:20:42.859 --> 00:20:45.319 meticulously evaluating the extent of any cystic 00:20:45.319 --> 00:20:48.519 bone loss and osseous erosions. It gives excellent 00:20:48.519 --> 00:20:50.819 bone detail, better than MRI in that regard. 00:20:50.990 --> 00:20:54.349 What about analyzing the joint fluid, arthrocentesis? 00:20:54.630 --> 00:20:56.890 Yes, arthrocentesis, aspirating the joint fluid, 00:20:57.230 --> 00:20:59.309 is indicated for patients presenting with recurrent 00:20:59.309 --> 00:21:02.029 hemathrosis. Analysis of the aspirated fluid 00:21:02.029 --> 00:21:04.049 typically reveals a grossly bloody effusion. 00:21:04.289 --> 00:21:06.910 It might appear dark brown or even blackish due 00:21:06.910 --> 00:21:08.750 to the breakdown products of hemoglobin over 00:21:08.750 --> 00:21:10.930 time. And the final confirmation. The definitive 00:21:10.930 --> 00:21:12.950 diagnosis is typically achieved through diagnostic 00:21:12.950 --> 00:21:15.529 arthroscopy combined with synovial biopsy. Looking 00:21:15.529 --> 00:21:18.589 inside the joint. Exactly. Arthroscopy allows 00:21:18.589 --> 00:21:21.490 for direct visualization. The clinician will 00:21:21.490 --> 00:21:23.410 typically observe the characteristic brownish 00:21:23.410 --> 00:21:26.730 or reddish inflamed synovium, often with its 00:21:26.730 --> 00:21:29.450 distinctive frond -like papillary projections 00:21:29.450 --> 00:21:32.930 or villi. And then you take a piece. Precisely. 00:21:33.430 --> 00:21:35.630 A synovial biopsy taken during the procedure 00:21:35.630 --> 00:21:37.789 is then crucial for microscopic confirmation. 00:21:38.950 --> 00:21:42.309 Histopathological examination reveals those pathognomonic, 00:21:42.589 --> 00:21:45.289 hemocytarin -stained, multinucleated giant cells, 00:21:45.809 --> 00:21:48.269 along with the pigmented foam cells, the mononuclear 00:21:48.269 --> 00:21:50.829 stromal cells, and evidence of active cellular 00:21:50.829 --> 00:21:53.269 proliferation with those mitotic figures we talked 00:21:53.269 --> 00:21:56.009 about. So biopsy confirms it. Any blood tests? 00:21:56.319 --> 00:21:58.640 It's worth noting that routine laboratory tests, 00:21:58.759 --> 00:22:01.940 things like C -reactive protein, CRP, and erythrocyte 00:22:01.940 --> 00:22:04.440 sedimentation rate, ESR, which are markers of 00:22:04.440 --> 00:22:06.980 systemic inflammation, are often completely normal 00:22:06.980 --> 00:22:09.940 in PVNS patients, despite the visible soft tissue 00:22:09.940 --> 00:22:12.019 swelling and the local inflammatory processes 00:22:12.019 --> 00:22:13.960 happening in the joint. So normal inflammatory 00:22:13.960 --> 00:22:16.339 markers can be misleading. They can, unfortunately. 00:22:16.519 --> 00:22:19.019 It can contribute to the delayed diagnosis by 00:22:19.019 --> 00:22:21.160 steering clinicians away from inflammatory causes 00:22:21.160 --> 00:22:23.019 when these markers are within normal limits. 00:22:23.400 --> 00:22:26.200 That comprehensive diagnostic pathway truly underscores 00:22:26.200 --> 00:22:29.319 the complexity. Okay, so once we've navigated 00:22:29.319 --> 00:22:31.680 that labyrinth and finally confirmed a diagnosis, 00:22:32.200 --> 00:22:34.460 what are the established and indeed the emerging 00:22:34.460 --> 00:22:37.539 strategies for managing PVNS, especially given 00:22:37.539 --> 00:22:39.839 its relentless tendency for local aggression 00:22:39.839 --> 00:22:42.839 and that high recurrence rate? It sounds like 00:22:42.839 --> 00:22:45.579 a multi -pronged approach is often necessary. 00:22:45.819 --> 00:22:47.980 You're absolutely right. A multimodal approach 00:22:47.980 --> 00:22:51.039 is essential because PB &S is fundamentally a 00:22:51.039 --> 00:22:53.660 locally destructive process. It actively invades 00:22:53.660 --> 00:22:56.019 and destroys healthy bone and cartilage and can 00:22:56.019 --> 00:22:59.319 grow to a significant size. Therefore, conservative 00:22:59.319 --> 00:23:01.519 management alone is generally ineffective and 00:23:01.519 --> 00:23:04.700 not recommended. So surgery is key. The cornerstone 00:23:04.700 --> 00:23:07.119 of treatment primarily involves surgical intervention, 00:23:07.480 --> 00:23:10.119 yes, to meticulously remove the tumor and the 00:23:10.119 --> 00:23:12.940 affected joint lining. The overarching goal is 00:23:12.940 --> 00:23:15.640 to achieve a maximal, if not complete, marginal 00:23:15.640 --> 00:23:18.559 excision of the diseased tissue. Okay. Tell us 00:23:18.559 --> 00:23:20.240 about the surgical procedures. Right. Surgical 00:23:20.240 --> 00:23:22.880 procedures remain the gold standard. For synovectomy, 00:23:23.019 --> 00:23:25.420 which is removal of the synovium, we differentiate 00:23:25.420 --> 00:23:27.720 based on the extent of the disease. Localized 00:23:27.720 --> 00:23:31.140 versus diffuse again. Exactly. Partial synovectomy 00:23:31.140 --> 00:23:33.400 is typically reserved for localized PV and S. 00:23:33.839 --> 00:23:35.900 This can often be performed arthroscopically. 00:23:36.059 --> 00:23:39.400 particularly for well -defined lesions in accessible 00:23:39.400 --> 00:23:42.920 areas like the anterior knee. Arthroscopic approaches 00:23:42.920 --> 00:23:44.980 offer significant advantages for the patient. 00:23:45.359 --> 00:23:48.299 Such as? Improved functional outcomes, better 00:23:48.299 --> 00:23:50.680 preservation of joint range of motion, and a 00:23:50.680 --> 00:23:53.200 much quicker recovery time compared to open surgery. 00:23:53.440 --> 00:23:57.059 Makes sense. And for diffuse? Well, for grossly 00:23:57.059 --> 00:24:00.420 symptomatic and painful diffused PD &S, a total 00:24:00.420 --> 00:24:03.099 synovectomy is indicated. The AIN here is the 00:24:03.099 --> 00:24:05.500 most complete possible removal of the entire 00:24:05.500 --> 00:24:07.880 joint lining. That sounds much more extensive. 00:24:08.119 --> 00:24:10.960 It often necessitates a fully open surgical approach, 00:24:11.220 --> 00:24:13.740 especially for extensive diffuse disease that 00:24:13.740 --> 00:24:15.500 involves both the front and back of the knee, 00:24:15.519 --> 00:24:18.400 for instance, to ensure a thorough excision of 00:24:18.400 --> 00:24:21.599 all affected tissue. In some complex cases, a 00:24:21.599 --> 00:24:23.759 combined approach might be employed perhaps open 00:24:23.759 --> 00:24:26.259 for the posterior knee, arthroscopic for the 00:24:26.259 --> 00:24:28.160 anterior, which can help to decrease the overall 00:24:28.160 --> 00:24:30.559 surgical invasiveness and potentially aid in 00:24:30.559 --> 00:24:32.920 patient recovery. What if a tendon is damaged? 00:24:33.380 --> 00:24:36.099 Ah, yes. If localized PVNS has caused damage 00:24:36.099 --> 00:24:38.779 to an adjacent tendon, for example, surgical 00:24:38.779 --> 00:24:41.059 repair would be undertaken concurrently during 00:24:41.059 --> 00:24:42.839 the tumor excision. And what if the joint is 00:24:42.839 --> 00:24:45.579 already severely damaged? Yes. For patients presenting 00:24:45.579 --> 00:24:48.619 with advanced disease and extensive joint destruction, 00:24:48.940 --> 00:24:51.240 more radical options become necessary. Like joint 00:24:51.240 --> 00:24:53.779 replacement? Total joint arthroplasty replacement, 00:24:53.960 --> 00:24:56.720 yes. A total knee, hip, or shoulder replacement 00:24:56.720 --> 00:24:59.500 may be required to relieve intractable pain and 00:24:59.500 --> 00:25:02.769 significantly improve function. However, it's 00:25:02.769 --> 00:25:05.210 critical for clinicians and surgeons to be aware 00:25:05.210 --> 00:25:08.569 that these procedures in PVNS patients are associated 00:25:08.569 --> 00:25:10.789 with higher rates of post -operative stiffness, 00:25:11.410 --> 00:25:14.230 heterotopic ossification, and even infection 00:25:14.230 --> 00:25:17.170 compared to standard indications like osteoarthritis. 00:25:17.190 --> 00:25:20.089 So higher risks. Definitely requires meticulous 00:25:20.089 --> 00:25:22.250 preoperative planning and post -operative care. 00:25:22.470 --> 00:25:25.259 Any other options for advanced disease? In severe 00:25:25.259 --> 00:25:27.420 end -stage cases, particularly involving joints 00:25:27.420 --> 00:25:29.779 like the ankle and arthritis or joint fusion, 00:25:30.259 --> 00:25:32.480 might be the only viable option to achieve pain 00:25:32.480 --> 00:25:35.240 relief and stability, albeit at the cost of mobility, 00:25:35.240 --> 00:25:37.779 of course. Okay, so surgery is central. What 00:25:37.779 --> 00:25:40.460 about other treatments? Radiation. Yes, beyond 00:25:40.460 --> 00:25:43.220 surgery, radiation therapy plays a crucial adjuvant 00:25:43.220 --> 00:25:46.759 role. particularly for widespread diffuse PVNS 00:25:46.759 --> 00:25:49.380 or in cases where surgical resection has been 00:25:49.380 --> 00:25:51.359 incomplete or unsuccessful. How does it help? 00:25:51.519 --> 00:25:53.920 Radiation can effectively shrink residual tumor 00:25:53.920 --> 00:25:56.460 burden and significantly reduce the likelihood 00:25:56.460 --> 00:25:59.579 of recurrence. What kind of radiation? Historically, 00:25:59.759 --> 00:26:02.619 external beam radiation was widely used. Typical 00:26:02.619 --> 00:26:05.839 doses were around 30, 35 gray and 15 fractions, 00:26:06.220 --> 00:26:09.299 or perhaps up to 50 gray and 25 fractions. Whilst 00:26:09.299 --> 00:26:12.099 effective, this approach carried potential complications. 00:26:12.440 --> 00:26:15.890 Skin necrosis, joint fibrosis, and in rare instances, 00:26:16.509 --> 00:26:18.710 radiation -induced sarcoma years later. Are there 00:26:18.710 --> 00:26:21.150 newer methods? Yes, a newer, often preferred 00:26:21.150 --> 00:26:23.829 method is intraarticular radiation synovectomy. 00:26:24.289 --> 00:26:26.309 This involves injecting a radioactive colloid 00:26:26.309 --> 00:26:28.549 directly into the joint space. It offers more 00:26:28.549 --> 00:26:30.950 localized treatment and generally fewer systemic 00:26:30.950 --> 00:26:32.990 side effects. And does combining surgery and 00:26:32.990 --> 00:26:36.329 radiation help? Crucially, yes. Contemporary 00:26:36.329 --> 00:26:38.750 evidence clearly demonstrates that when radiation 00:26:38.750 --> 00:26:41.910 therapy is combined with a total surgical synovectomy, 00:26:41.980 --> 00:26:44.619 It significantly reduces the recurrence rate 00:26:44.619 --> 00:26:47.599 of diffuse PDNS. It can bring it down to a more 00:26:47.599 --> 00:26:50.460 manageable range of approximately 10 -20%. 10 00:26:50.460 --> 00:26:53.660 -20%, down from 30 -50, that's a big difference. 00:26:53.839 --> 00:26:56.359 It is. This combination therapy has become a 00:26:56.359 --> 00:26:59.059 standard of care for extensive or recurrent disease. 00:26:59.339 --> 00:27:02.319 Any caveats? Children? Yes, a very important 00:27:02.319 --> 00:27:04.460 point. It's important to underscore that radiation 00:27:04.460 --> 00:27:07.319 is generally avoided in pediatric patients. This 00:27:07.319 --> 00:27:09.500 is due to the significant potential for growth 00:27:09.500 --> 00:27:12.200 plate damage, limb length discrepancies, and 00:27:12.200 --> 00:27:14.460 other serious long -term medical issues associated 00:27:14.460 --> 00:27:17.000 with radiation exposure and developing tissues. 00:27:17.339 --> 00:27:19.480 Right. Now, what about drug therapies? You mentioned 00:27:19.480 --> 00:27:21.740 targeted treatments earlier. Yes. Perhaps one 00:27:21.740 --> 00:27:23.940 of the most exciting and rapidly advancing areas 00:27:23.940 --> 00:27:27.000 is in emerging drug therapies, specifically molecular 00:27:27.000 --> 00:27:29.700 therapeutics. These treatments represent a real 00:27:29.700 --> 00:27:32.339 paradigm shift, moving towards medications that 00:27:32.339 --> 00:27:34.759 specifically target those identified molecular 00:27:34.759 --> 00:27:38.740 drivers of PVNS, particularly the CSF1R protein 00:27:38.740 --> 00:27:41.420 we discussed earlier. The receptor pathway. Exactly. 00:27:41.599 --> 00:27:43.920 Pexadart NIV is a leading example here. It was 00:27:43.920 --> 00:27:47.099 approved by the FDA back in August 2019. It's 00:27:47.099 --> 00:27:50.480 an oral CSF1R inhibitor indicated for adult patients 00:27:50.480 --> 00:27:53.180 with symptomatic tenosynovial giant cell tumor, 00:27:53.740 --> 00:27:56.960 which includes PDNS that's associated with severe 00:27:56.960 --> 00:27:59.920 morbidity or functional limitations and is not 00:27:59.920 --> 00:28:02.099 amenable to improvement with surgery. How effective 00:28:02.099 --> 00:28:04.799 is it? In clinical trials, this oral medication 00:28:04.970 --> 00:28:07.829 typically taken once daily for 24 weeks, has 00:28:07.829 --> 00:28:10.069 demonstrated significant improvement in the PVNS 00:28:10.069 --> 00:28:12.930 disease burden in approximately 40 % of patients. 00:28:13.589 --> 00:28:15.769 It leads to substantial tumor shrinkage and symptom 00:28:15.769 --> 00:28:17.910 alleviation. It's really been a game changer 00:28:17.910 --> 00:28:21.009 for those with extensive surgically complex or 00:28:21.009 --> 00:28:23.430 recurrent disease. 40 % response is significant. 00:28:23.609 --> 00:28:26.049 Are there others in development? Yes. Other promising 00:28:26.049 --> 00:28:29.130 agents are also under investigation. Imakazumab 00:28:29.130 --> 00:28:31.910 is a monoclonal antibody that directly targets 00:28:31.910 --> 00:28:35.289 CSF1R, effectively blocking the signaling pathway. 00:28:36.509 --> 00:28:39.750 PLX3397 is another oral tyrosine kinase inhibitor 00:28:39.750 --> 00:28:43.009 that, similar to Pixadertinib, also inhibits 00:28:43.009 --> 00:28:46.190 CSF1R. Both of these agents have shown objective 00:28:46.190 --> 00:28:48.990 clinical responses in early phase trials, further 00:28:48.990 --> 00:28:51.369 underscoring the validity of targeting the CSF1 00:28:51.369 --> 00:28:53.910 pathway. And combination therapies. Current research 00:28:53.910 --> 00:28:56.369 is also vigorously exploring combination therapies. 00:28:56.869 --> 00:28:59.529 For instance, combining CSF1R inhibitors with 00:28:59.529 --> 00:29:03.009 other targeted agents, perhaps anti -PD -L1 immunotherapy, 00:29:03.410 --> 00:29:07.710 or PA3 -carodact pathway inhibitors like LY294002 00:29:07.710 --> 00:29:10.309 hold significant promise. Why combine them? The 00:29:10.309 --> 00:29:12.410 rationale here is to potentially enhance response 00:29:12.410 --> 00:29:14.809 rates, maybe overcome resistance mechanisms that 00:29:14.809 --> 00:29:16.950 might develop, and improve the durability of 00:29:16.950 --> 00:29:19.059 the treatment. Ultimately, the aim is to further 00:29:19.059 --> 00:29:21.019 improve long -term outcomes and potentially reduce 00:29:21.019 --> 00:29:23.039 the need for repeat surgeries or the progression 00:29:23.039 --> 00:29:25.859 to end -stage joint destruction. This multimodal 00:29:25.859 --> 00:29:28.539 and increasingly targeted approach is truly defining 00:29:28.539 --> 00:29:30.940 the contemporary management of PVNS. It's clear 00:29:30.940 --> 00:29:33.299 that the treatment landscape for PVNS is evolving 00:29:33.299 --> 00:29:36.279 incredibly rapidly, offering a much more diverse 00:29:36.279 --> 00:29:38.880 arsenal than ever before. It's quite hopeful. 00:29:39.039 --> 00:29:41.740 It is. But beyond the immediate intervention, 00:29:41.960 --> 00:29:45.009 whatever it may be, What does the recovery process 00:29:45.009 --> 00:29:47.390 typically look like for a patient who has undergone 00:29:47.390 --> 00:29:50.089 these treatments? And crucially, what are the 00:29:50.089 --> 00:29:52.509 potential pitfalls and complications that we 00:29:52.509 --> 00:29:55.390 as clinicians, and indeed our patients, need 00:29:55.390 --> 00:29:58.930 to be acutely aware of, particularly that notorious 00:29:58.930 --> 00:30:02.309 issue of recurrence? Recovery from PVNS treatment, 00:30:02.529 --> 00:30:04.789 especially surgical intervention, is definitely 00:30:04.789 --> 00:30:07.470 a journey. It requires significant patient commitment 00:30:07.470 --> 00:30:11.190 and meticulous clinical oversight. And yes, vigilance 00:30:11.190 --> 00:30:14.250 for potential complications is key. Rehabilitation 00:30:14.250 --> 00:30:16.609 is absolutely paramount post -surgery. Physical 00:30:16.609 --> 00:30:19.089 therapy. Exactly. To ensure patients regain as 00:30:19.089 --> 00:30:20.990 much strength and range of motion as possible. 00:30:21.289 --> 00:30:23.269 That directly correlates with their long -term 00:30:23.269 --> 00:30:25.829 functional outcome. Does it differ based on the 00:30:25.829 --> 00:30:29.410 type of surgery? Yes, significantly. For those 00:30:29.410 --> 00:30:32.130 undergoing arthroscopic surgery, typically for 00:30:32.130 --> 00:30:35.390 localized PD &S, the recovery is generally quicker 00:30:35.390 --> 00:30:38.940 and less arduous. It usually requires a focused, 00:30:39.279 --> 00:30:41.599 shorter course of physical therapy. This often 00:30:41.599 --> 00:30:44.099 allows for a relatively swift return to normal 00:30:44.099 --> 00:30:47.059 daily activities. And open surgery. However, 00:30:47.619 --> 00:30:50.039 open surgical procedures, particularly those 00:30:50.039 --> 00:30:52.680 extensive total synovectomies for diffuse PVNS, 00:30:53.180 --> 00:30:56.240 are far more invasive. These carry a significantly 00:30:56.240 --> 00:30:59.319 increased risk of post -operative stiffness and 00:30:59.319 --> 00:31:02.049 scar tissue formation. Meaning longer rehab. 00:31:02.509 --> 00:31:04.970 Yes. Necessitating a much more regimented and 00:31:04.970 --> 00:31:07.549 prolonged physical therapy program, often spanning 00:31:07.549 --> 00:31:10.329 several months, to really optimize joint mobility 00:31:10.329 --> 00:31:13.369 and overall function. Okay. Now about those complications. 00:31:13.769 --> 00:31:15.990 Recurrence is the big one. It is. The most frequent 00:31:15.990 --> 00:31:17.869 and indeed the most challenging complication 00:31:17.869 --> 00:31:21.049 is recurrence. While localized PVNS rarely recurs 00:31:21.049 --> 00:31:23.650 after complete surgical excision, the diffuse 00:31:23.650 --> 00:31:26.269 form, as we've said, has a notoriously high recurrence 00:31:26.269 --> 00:31:28.299 rate. Even after apparently complete surgery? 00:31:28.839 --> 00:31:30.960 Yes. Despite what might be considered a complete 00:31:30.960 --> 00:31:32.920 synovectomy, recurrence rates can range from 00:31:32.920 --> 00:31:36.039 10 % to as high as 50%. Why so high? It's often 00:31:36.039 --> 00:31:38.619 attributed to the inherent difficulty in achieving 00:31:38.619 --> 00:31:41.559 a truly complete excision, simply due to the 00:31:41.559 --> 00:31:45.519 infiltrative nature of diffused disease. Microscopic 00:31:45.519 --> 00:31:47.759 remnants of the abnormal synovium can persist 00:31:47.759 --> 00:31:50.259 and lead to subsequent regrowth. And how do we 00:31:50.259 --> 00:31:52.779 mitigate that? As we touched upon, one of the 00:31:52.779 --> 00:31:55.099 most effective strategies is combining surgery 00:31:55.099 --> 00:31:57.660 with adjuvant external beam radiation therapy. 00:31:58.539 --> 00:32:00.940 That can significantly reduce recurrence rates 00:32:00.940 --> 00:32:04.259 down to that more manageable 10 -20 % range for 00:32:04.259 --> 00:32:06.859 diffuse PVNS. Right. What other complications 00:32:06.859 --> 00:32:09.400 should we be aware of? Beyond recurrence, several 00:32:09.400 --> 00:32:12.420 other complications can arise. If PVNS is left 00:32:12.420 --> 00:32:15.019 untreated, or if it progresses despite therapy, 00:32:15.559 --> 00:32:17.980 it inevitably leads to moderate to severe joint 00:32:17.980 --> 00:32:20.559 deformity, progressive degenerative articular 00:32:20.559 --> 00:32:23.500 changes, and ultimately debilitating osteoarthritis. 00:32:23.579 --> 00:32:26.240 Leading to fusion or replacement anyway. Exactly. 00:32:26.460 --> 00:32:29.460 In the most severe and intractable cases, the 00:32:29.460 --> 00:32:31.359 relentless cortical bone destruction and joint 00:32:31.359 --> 00:32:33.779 damage may necessitate more extreme interventions 00:32:33.779 --> 00:32:36.740 like arthrodesis or, in exceptionally rare and 00:32:36.740 --> 00:32:39.319 desperate circumstances, even amputation of the 00:32:39.319 --> 00:32:41.480 affected limb. Gosh, and risks from the treatments 00:32:41.480 --> 00:32:44.220 themselves. Yes, there are specific treatment 00:32:44.220 --> 00:32:46.539 -related risks that we must carefully consider 00:32:46.539 --> 00:32:49.259 and discuss with patients. For patients receiving 00:32:49.259 --> 00:32:52.140 Pexadartinib, the primary and most serious risk 00:32:52.140 --> 00:32:55.910 is hepatic toxicity. Liver problems. Oh, serious. 00:32:56.109 --> 00:32:58.170 It can range from transient elevation of liver 00:32:58.170 --> 00:33:00.730 enzymes to severe and potentially fatal liver 00:33:00.730 --> 00:33:03.809 injury. This necessitates close and vigilant 00:33:03.809 --> 00:33:06.710 monitoring of liver function tests, specifically 00:33:06.710 --> 00:33:09.369 AST and ALT, throughout the treatment course. 00:33:09.589 --> 00:33:11.789 Any other side effects of pexadortinib? Hair 00:33:11.789 --> 00:33:14.210 depigmentation is another commonly noted, though 00:33:14.210 --> 00:33:16.549 obviously less serious, side effect. Okay. And 00:33:16.549 --> 00:33:19.230 surgical risks. Surgical approaches also carry 00:33:19.230 --> 00:33:21.930 their own set of risks, of course. Open surgeries 00:33:21.930 --> 00:33:24.369 by their nature are associated with longer hospital 00:33:24.369 --> 00:33:27.569 stays, increased post -operative pain, and more 00:33:27.569 --> 00:33:30.349 prolonged rehabilitation periods. For instance, 00:33:30.849 --> 00:33:33.049 extensive posterior approaches to the knee, while 00:33:33.049 --> 00:33:35.750 sometimes unavoidable for diffuse disease, place 00:33:35.750 --> 00:33:38.109 critical neurovascular structures like the popliteal 00:33:38.109 --> 00:33:40.750 artery and nerve at risk. And arthroscopy, less 00:33:40.750 --> 00:33:44.569 risky. Less invasive, yes, but it demands considerable 00:33:44.569 --> 00:33:47.619 technical expertise. and it may be less effective 00:33:47.619 --> 00:33:50.440 for very large masses or those with significant 00:33:50.440 --> 00:33:53.680 local tissue invasion. Making a truly complete 00:33:53.680 --> 00:33:56.880 excision challenging arthroscopically can potentially 00:33:56.880 --> 00:33:59.279 lead to higher recurrence rates if not performed 00:33:59.279 --> 00:34:01.599 meticulously. And radiation risks. Radiation 00:34:01.599 --> 00:34:04.079 therapy, while effective in reducing recurrence, 00:34:04.359 --> 00:34:07.359 carries risks including local skin changes, fibrosis, 00:34:07.519 --> 00:34:10.019 and in extremely rare cases, the induction of 00:34:10.019 --> 00:34:12.619 a secondary radiation -induced sarcoma many years 00:34:12.619 --> 00:34:14.780 post -treatment. Finally, what about spread? 00:34:15.280 --> 00:34:18.400 Metastasis. Right. While PVNS is overwhelmingly 00:34:18.400 --> 00:34:20.920 a localized disease, it is important to acknowledge 00:34:20.920 --> 00:34:23.199 that there have been exceedingly rare documented 00:34:23.199 --> 00:34:26.380 instances of metastasis to distant sites, lungs, 00:34:26.719 --> 00:34:29.000 muscles, regional lymph nodes. But very rare. 00:34:29.300 --> 00:34:31.380 Exceptionally rare. And it's absolutely crucial 00:34:31.380 --> 00:34:34.000 to emphasize that this is far more commonly associated 00:34:34.000 --> 00:34:36.360 with the truly malignant forms of tenosynovial 00:34:36.360 --> 00:34:39.340 giant cell tumors rather than the typically benign, 00:34:39.460 --> 00:34:41.820 albeit locally aggressive, PVNS we're mostly 00:34:41.820 --> 00:34:44.179 discussing. That distinction is very important 00:34:44.179 --> 00:34:46.699 for patient counseling and prognostication. That's 00:34:46.699 --> 00:34:49.639 a comprehensive and frankly quite sobering overview 00:34:49.639 --> 00:34:52.179 of the challenges in recovery and the potential 00:34:52.179 --> 00:34:55.400 complications. It truly reinforces the need for 00:34:55.400 --> 00:34:57.739 ongoing vigilance and careful management. It 00:34:57.739 --> 00:35:00.559 does. Despite these hurdles. What's the long 00:35:00.559 --> 00:35:02.699 -term outlook generally for patients diagnosed 00:35:02.699 --> 00:35:05.880 with PVNS? And perhaps more optimistically, what 00:35:05.880 --> 00:35:08.159 exciting avenues are researchers currently exploring 00:35:08.159 --> 00:35:10.400 to improve patient care and those long -term 00:35:10.400 --> 00:35:13.679 outcomes? Well, the prognosis for PVNS from a 00:35:13.679 --> 00:35:16.059 life expectancy perspective is generally good. 00:35:16.440 --> 00:35:19.000 It's rarely a fatal disease. That's reassuring. 00:35:19.260 --> 00:35:22.260 It is. However, its primary impact is really 00:35:22.260 --> 00:35:24.579 on the patient's quality of life. It's a condition 00:35:24.579 --> 00:35:27.110 that relentlessly erodes joint function. leading 00:35:27.110 --> 00:35:30.030 to chronic pain, reduced mobility, and considerable 00:35:30.030 --> 00:35:32.110 difficulty with daily activities. So function 00:35:32.110 --> 00:35:34.769 is the main issue? Primarily, yes. The long -term 00:35:34.769 --> 00:35:36.510 outlook for functional preservation ultimately 00:35:36.510 --> 00:35:39.469 hinges on several intertwined factors. The initial 00:35:39.469 --> 00:35:42.170 size and anatomical location of the tumor, the 00:35:42.170 --> 00:35:44.590 extent of its spread localized versus diffuse, 00:35:44.929 --> 00:35:47.449 and most critically, the timeliness and efficacy 00:35:47.449 --> 00:35:49.429 of the chosen treatment. And recurrence plays 00:35:49.429 --> 00:35:52.809 a big role. Absolutely. While surgical cure is 00:35:52.809 --> 00:35:55.090 certainly achievable, particularly for the localized 00:35:55.090 --> 00:35:58.150 form, the persistent high recurrence rate of 00:35:58.150 --> 00:36:01.429 diffuse PVNS means that accelerated degenerative 00:36:01.429 --> 00:36:04.349 changes within the joint are a common long -term 00:36:04.349 --> 00:36:07.289 reality. This often leads to the eventual need 00:36:07.289 --> 00:36:09.769 for a total joint arthroplasty to manage pain 00:36:09.769 --> 00:36:12.380 and restore some semblance of function. And you 00:36:12.380 --> 00:36:14.739 mentioned replacements in PVNS patients have 00:36:14.739 --> 00:36:17.320 unique issues. Yes. It's vital for orthopedic 00:36:17.320 --> 00:36:19.380 surgeons to be aware that total knee arthroplasty, 00:36:19.380 --> 00:36:21.480 for example, when performed in patients with 00:36:21.480 --> 00:36:24.239 a history of PVNS, is indeed associated with 00:36:24.239 --> 00:36:26.619 its own unique set of complication rates, often 00:36:26.619 --> 00:36:28.980 higher rates of stiffness, infection, and even 00:36:28.980 --> 00:36:31.719 recurrence of PVNS around the prosthesis, compared 00:36:31.719 --> 00:36:34.440 to standard osteoarthritis indications. This 00:36:34.440 --> 00:36:36.579 necessitates specific surgical considerations 00:36:36.579 --> 00:36:38.739 and thorough patient counseling. Right. Looking 00:36:38.739 --> 00:36:40.579 to the future, then. What's happening in research? 00:36:40.840 --> 00:36:43.139 The landscape of PVNS research is incredibly 00:36:43.139 --> 00:36:45.980 vibrant and advancing at a rapid pace. This is 00:36:45.980 --> 00:36:47.980 largely driven by the identification of those 00:36:47.980 --> 00:36:50.500 key genetic and molecular factors, particularly 00:36:50.500 --> 00:36:54.340 the CSF1R pathway. Beyond CSF1R. Researchers 00:36:54.340 --> 00:36:57.420 are actively investigating novel molecular targets 00:36:57.420 --> 00:37:02.210 beyond just CSF1R. For instance, factors like 00:37:02.210 --> 00:37:06.449 PLIN, PPP -2A, and Tyro -BP have been identified 00:37:06.449 --> 00:37:08.329 as potentially playing roles in the disease's 00:37:08.329 --> 00:37:10.989 pathogenesis. Understanding their specific involvement 00:37:10.989 --> 00:37:14.090 could unlock entirely new diagnostic biomarkers 00:37:14.090 --> 00:37:16.329 and, more importantly, innovative therapeutic 00:37:16.329 --> 00:37:18.630 strategies targeting different pathways. That 00:37:18.630 --> 00:37:20.590 could potentially improve patient outcomes even 00:37:20.590 --> 00:37:23.110 further. And improving current therapies. Yes. 00:37:23.469 --> 00:37:26.050 A significant area of focus is also on optimizing 00:37:26.050 --> 00:37:28.849 existing therapies. There are extensive ongoing 00:37:28.849 --> 00:37:31.440 efforts to refine of targeted molecular therapies, 00:37:31.940 --> 00:37:34.780 like Pexamartinib and other CSF1R inhibitors. 00:37:35.019 --> 00:37:37.699 This includes exploring optimal dosing regimens, 00:37:37.900 --> 00:37:39.820 duration of treatment, and identifying patient 00:37:39.820 --> 00:37:42.420 subgroups who might respond best, or conversely 00:37:42.420 --> 00:37:44.900 those likely to develop resistance. Furthermore, 00:37:45.079 --> 00:37:47.099 there's considerable research into various combination 00:37:47.099 --> 00:37:50.360 approaches. We talked about that. Exactly. combining 00:37:50.360 --> 00:37:54.719 anti -PD -L1 immunotherapy with CSF1R inhibitors 00:37:54.719 --> 00:37:58.960 or integrating PI3K pathway inhibitors, the rationale 00:37:58.960 --> 00:38:01.599 is that by hitting multiple targets or modulating 00:38:01.599 --> 00:38:03.800 the tumor microenvironment, we can enhance the 00:38:03.800 --> 00:38:06.159 efficacy of treatment, potentially overcome resistance, 00:38:06.639 --> 00:38:08.659 and more effectively slow down disease progression, 00:38:09.480 --> 00:38:11.519 ultimately aiming to reduce joint deterioration 00:38:11.519 --> 00:38:13.599 and profoundly alleviate symptoms for longer. 00:38:13.849 --> 00:38:15.789 That sounds promising. Are there challenges in 00:38:15.789 --> 00:38:17.849 the research itself? There are. It's crucial 00:38:17.849 --> 00:38:19.949 to acknowledge the research challenges that persist 00:38:19.949 --> 00:38:23.190 in a rare disease like PVNS. Many existing studies, 00:38:23.449 --> 00:38:25.349 particularly those investigating novel therapies, 00:38:25.849 --> 00:38:28.329 often involve relatively small sample sizes simply 00:38:28.329 --> 00:38:30.449 due to the low incidence, and sometimes they 00:38:30.449 --> 00:38:32.309 have shorter follow -up durations. So we need 00:38:32.309 --> 00:38:35.510 bigger, longer studies. Exactly. This highlights 00:38:35.510 --> 00:38:38.889 a clear and pressing need for larger, multi -center 00:38:38.889 --> 00:38:41.769 international trials with extended follow -up 00:38:41.769 --> 00:38:45.219 periods. Such robust trials are essential to 00:38:45.219 --> 00:38:48.260 rigorously validate current findings, to fully 00:38:48.260 --> 00:38:50.820 unravel the complex genetic heterogeneity of 00:38:50.820 --> 00:38:53.699 PVNS, and to comprehensively assess the long 00:38:53.699 --> 00:38:56.699 -term efficacy and safety profiles of these newer, 00:38:56.860 --> 00:38:59.500 targeted treatments in diverse patient populations. 00:38:59.719 --> 00:39:03.179 But overall, there's hope. Definitely. The evolving 00:39:03.179 --> 00:39:05.860 landscape of PVNS management offers significant 00:39:05.860 --> 00:39:08.679 hope, particularly through these molecular breakthroughs, 00:39:08.860 --> 00:39:10.960 for dramatically improving the long -term quality 00:39:10.960 --> 00:39:13.440 of life and functional prognosis for our patients. 00:39:13.880 --> 00:39:16.119 That vision for the future certainly offers a 00:39:16.119 --> 00:39:19.219 great deal of hope. And given the really multifaceted 00:39:19.219 --> 00:39:21.739 nature of this condition, from the delayed diagnosis 00:39:21.739 --> 00:39:23.679 right through to complex treatment and long -term 00:39:23.679 --> 00:39:25.920 management, it truly sounds like a condition 00:39:25.920 --> 00:39:28.300 that benefits immensely from a properly joined 00:39:28.300 --> 00:39:31.239 up approach. Absolutely. What, then, is the best 00:39:31.239 --> 00:39:33.559 way for healthcare professionals across different 00:39:33.559 --> 00:39:36.360 specialties to collaborate effectively for optimal 00:39:36.360 --> 00:39:39.420 patient outcomes in PVNS, integrating all these 00:39:39.420 --> 00:39:42.099 various facets of care we've discussed. You've 00:39:42.099 --> 00:39:43.619 highlighted perhaps the most critical element 00:39:43.619 --> 00:39:46.179 for achieving the best possible outcomes in PVNS, 00:39:46.960 --> 00:39:49.659 a comprehensive interprofessional team approach. 00:39:49.960 --> 00:39:52.320 This model goes beyond simply referring a patient 00:39:52.320 --> 00:39:55.340 between specialists. It really integrates individual 00:39:55.340 --> 00:39:58.519 patient goals, establishes realistic functional 00:39:58.519 --> 00:40:01.340 outcomes, and ensures a truly coordinated care 00:40:01.340 --> 00:40:03.900 pathway across multiple disciplines. Where does 00:40:03.900 --> 00:40:06.960 that collaboration start? Diagnosis. Firstly, 00:40:07.179 --> 00:40:09.559 yes, the diagnosis is optimally established through 00:40:09.559 --> 00:40:11.239 the collaborative effort of the primary care 00:40:11.239 --> 00:40:13.800 physician, who often first raises this suspicion 00:40:13.800 --> 00:40:16.900 alongside radiologists, providing those critical 00:40:16.900 --> 00:40:19.619 imaging insights and pathologists who give the 00:40:19.619 --> 00:40:22.219 definitive microscopic confirmation from biopsy. 00:40:23.019 --> 00:40:26.139 This upfront, coordinated collaboration ensures 00:40:26.139 --> 00:40:28.679 the correct imaging studies are ordered and interpreted 00:40:28.679 --> 00:40:31.139 accurately, leading to informed decisions about 00:40:31.139 --> 00:40:33.659 the need for biopsy. It minimizes diagnostic 00:40:33.659 --> 00:40:35.860 delays and ensures the patient gets onto the 00:40:35.860 --> 00:40:37.860 correct treatment pathway as early as possible. 00:40:38.280 --> 00:40:41.340 And once diagnosed. Once a diagnosis is confirmed, 00:40:42.320 --> 00:40:44.159 multidisciplinary treatment planning becomes 00:40:44.159 --> 00:40:47.190 paramount. The core care team typically includes 00:40:47.190 --> 00:40:50.369 orthopedic surgeons, oncologists especially if 00:40:50.369 --> 00:40:52.869 systemic therapy or radiation is being considered, 00:40:53.449 --> 00:40:55.530 and clinical pharmacists. How should they work 00:40:55.530 --> 00:40:58.309 together? These professionals should engage in 00:40:58.309 --> 00:41:00.349 open, transparent discussions with the patient. 00:41:01.240 --> 00:41:03.440 collaboratively establishing patient care goals, 00:41:04.000 --> 00:41:07.199 and meticulously weighing the risks versus benefits 00:41:07.199 --> 00:41:10.280 of surgical intervention versus systemic treatments. 00:41:10.900 --> 00:41:13.380 For example, considering an oral medication like 00:41:13.380 --> 00:41:16.219 pexadartinib for extensive diffuse disease, where 00:41:16.219 --> 00:41:18.480 surgery is unlikely to succeed without prohibitive 00:41:18.480 --> 00:41:21.199 morbidity, particularly in patients without major 00:41:21.199 --> 00:41:24.099 hepatic comorbidities, that's a decision best 00:41:24.099 --> 00:41:26.500 made collectively after a thorough case discussion 00:41:26.500 --> 00:41:28.730 involving everyone. The pharmacist's role. The 00:41:28.730 --> 00:41:31.070 pharmacy team plays a vital, often understated 00:41:31.070 --> 00:41:34.150 role in medical treatment, meticulously verifying 00:41:34.150 --> 00:41:37.369 ghosting, ensuring proper administration, diligently 00:41:37.369 --> 00:41:40.369 checking for potential drug interactions or contraindications, 00:41:40.809 --> 00:41:42.989 especially crucial with these novel molecular 00:41:42.989 --> 00:41:45.610 therapies. And nursing and therapy support. Throughout 00:41:45.610 --> 00:41:48.190 the entire diagnostic, treatment, and post -operative 00:41:48.190 --> 00:41:50.849 phases, nursing staff with specialist training 00:41:50.849 --> 00:41:53.909 in orthopedics and surgical care provide crucial 00:41:53.909 --> 00:41:57.050 patient support, continuous evaluation, and tailored 00:41:57.050 --> 00:42:00.550 counseling. If surgery is the chosen path, physical 00:42:00.550 --> 00:42:03.210 therapists are absolutely indispensable for guiding 00:42:03.210 --> 00:42:05.710 the rehabilitation process, helping patients 00:42:05.710 --> 00:42:08.349 regain function, restore range of motion, and 00:42:08.349 --> 00:42:11.409 rebuild muscle strength. And the effective management 00:42:11.409 --> 00:42:13.869 of pain, which can be a common and persistent 00:42:13.869 --> 00:42:16.469 symptom, should actively involve the pharmacist 00:42:16.469 --> 00:42:19.550 to ensure effective and safe analgesic strategies 00:42:19.550 --> 00:42:21.750 are implemented, considering the potential for 00:42:21.750 --> 00:42:25.030 chronic pain. So it's a whole team effort. Absolutely. 00:42:25.469 --> 00:42:27.909 By embracing this interprofessional team paradigm 00:42:27.909 --> 00:42:29.969 where all these disciplines collaborate seamlessly, 00:42:30.349 --> 00:42:32.750 we can ensure the most comprehensive and effective 00:42:32.750 --> 00:42:35.329 patient outcomes, regardless of the specific 00:42:35.329 --> 00:42:37.469 management pathway chosen. Anything else. And 00:42:37.469 --> 00:42:40.409 I must underscore a crucial, often underutilized 00:42:40.409 --> 00:42:42.869 element in this collaborative framework, patient 00:42:42.869 --> 00:42:45.090 empowerment. Involving the patient more. Actively 00:42:45.090 --> 00:42:46.929 increasing the patient's role in constructing 00:42:46.929 --> 00:42:49.670 their collaborative treatment plan is not only 00:42:49.670 --> 00:42:52.659 ethically sound, but is also empirically proven 00:42:52.659 --> 00:42:55.400 to solidify patient compliance and significantly 00:42:55.400 --> 00:42:58.480 improve long -term outcomes, not just in PVNS, 00:42:58.599 --> 00:43:01.320 but across the entire spectrum of complex diseases. 00:43:02.380 --> 00:43:04.500 Continued patient -physician collaboration right 00:43:04.500 --> 00:43:06.800 from the initial diagnosis through treatment 00:43:06.800 --> 00:43:09.800 and ongoing long -term management is unequivocally 00:43:09.800 --> 00:43:12.059 advised for this challenging condition. That's 00:43:12.059 --> 00:43:14.519 a fantastic point to end on the power of the 00:43:14.519 --> 00:43:17.179 informed, engaged patient within that collaborative 00:43:17.179 --> 00:43:20.280 team. What an extraordinary, albeit challenging 00:43:20.280 --> 00:43:22.980 journey we've taken into the world of pigmented 00:43:22.980 --> 00:43:26.340 villinodular synovitis today. We've certainly 00:43:26.340 --> 00:43:28.360 had a truly comprehensive exploration, haven't 00:43:28.360 --> 00:43:30.960 we? Covering everything from its rare incidence 00:43:30.960 --> 00:43:33.539 and the complex pathophysiology driven by that 00:43:33.539 --> 00:43:36.179 CSF1R pathway right through to its varied and 00:43:36.179 --> 00:43:38.280 often deceiving clinical presentations and the 00:43:38.280 --> 00:43:40.239 cutting edge multimodal treatments now available. 00:43:41.280 --> 00:43:45.340 the profound importance of an integrated multidisciplinary 00:43:45.340 --> 00:43:48.300 approach and genuine patient involvement truly 00:43:48.300 --> 00:43:50.719 shines through as the cornerstone of effective 00:43:50.719 --> 00:43:54.000 management. Ultimately, understanding PVNS isn't 00:43:54.000 --> 00:43:56.039 just about dissecting its intricate biology, 00:43:56.199 --> 00:43:58.940 is it? It's about appreciating the nuanced and 00:43:58.940 --> 00:44:02.119 often protracted patient journey and that relentless 00:44:02.119 --> 00:44:04.679 pursuit of better quality of life in the face 00:44:04.679 --> 00:44:07.699 of a persistent locally aggressive disease. Well 00:44:07.699 --> 00:44:10.190 said. If you found this deep dive insightful, 00:44:10.710 --> 00:44:12.909 please do consider rating and sharing the deep 00:44:12.909 --> 00:44:14.929 dive with a colleague who might also benefit 00:44:14.929 --> 00:44:17.409 from these insights. Thank you so much for joining 00:44:17.409 --> 00:44:19.610 us and sharing your invaluable expertise today. 00:44:19.949 --> 00:44:21.630 It's been my pleasure. It's certainly a field 00:44:21.630 --> 00:44:23.650 experiencing rapid advancements, particularly 00:44:23.650 --> 00:44:26.349 with these molecular therapies, and staying abreast 00:44:26.349 --> 00:44:28.429 of these developments truly offers significant 00:44:28.429 --> 00:44:30.929 hope for revolutionizing long -term outcomes 00:44:30.929 --> 00:44:31.670 for our patients.